TB-403 clinical trials
Also written RO5323441.
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses TB-403 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2018 (2)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2016 | 1 |
| 2018 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Hoffmann-La Roche (2) · BioInvent International AB (1) · Oncurious NV (1) · ThromboGenics (1) · Oxurion (1)
Studies
Open first, then newest update. How each study uses TB-403 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Phase I Study on Monoclonal Antibody TB-403 Directed Against PlGF in Patients With Solid TumoursCompletedPhase 1BioInvent International ABNCT00702494Written as TB-403How we know
- A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory MedulloblastomaCompletedPhase 1Oncurious NVNCT02748135Written as TB-403 20mg/kgHow we know
- A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)CompletedPhase 2ThromboGenicsNCT03669393Written as THR-317 8mgHow we know
- A Study to Evaluate THR-317 and Ranibizumab Combination Treatment for Diabetic Macular Oedema (DME)CompletedPhase 2OxurionNCT03499223Written as THR-317 8mgHow we know
- A Dose-finding Study of RO5323441 in Patients With Metastatic Treatment-Refractory Colorectal or Ovarian CancerCompletedPhase 1Hoffmann-La RocheNCT01148758Written as RO5323441How we know
- A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular CarcinomaCompletedPhase 1Hoffmann-La RocheNCT01308723Written as RO5323441How we know
Codes
What other systems call TB-403 · ClinicalTrials.gg INT005989
- MeSH (NLM) C569915TB-403One source NLM
- UNII (FDA) 46MVG4H2LFTB-403Confirmed FDA, NLM
- NCI Thesaurus C78486Anti-PLGF Monoclonal Antibody TB-403One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C569915 | TB-403 | One source NLM |
| UNII (FDA) | 46MVG4H2LF | TB-403 | Confirmed FDA, NLM |
| NCI Thesaurus | C78486 | Anti-PLGF Monoclonal Antibody TB-403 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.